Skip to Main Content

A flick of the prescriber’s pen could save $825 million a year on lung cancer care in the U.S.

That’s the finding of a new study on the immunotherapy drug pembrolizumab, marketed commercially as Keytruda by Merck. By switching to weight-based dosing — instead of a fixed dose of 200 mg — doctors could quickly reduce costs of the intravenous therapy without compromising its effectiveness, the study concludes.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


Comments are closed.